Cardinal Health (CAH) reported Q3 earnings per share of $3.17, surpassing the Zacks Consensus Estimate of $2.80 and significantly exceeding the year-ago figure of $2.35. The quarterly results reflect a positive earnings surprise of 13.22%, continuing a streak where the company has beaten consensus EPS...
William Blair has initiated coverage on Cardinal Health (NYSE: CAH) with an Outperform rating, positioning the pharma distributor as a "stealth compounder" driven by a durable competitive moat. The firm highlights that Cardinal's distribution platform and scale allow it to capture value from demographic tailwinds...
Cardinal Health (CAH) shares closed down 1.64% at $222.04, continuing a broader decline for the stock over the past month which saw a 2.85% drop. This underperformance occurred while the wider Medical sector fell 3.65%, contrasting with gains in the Nasdaq and S&P 500. Analysts...
Cardinal Health (CAH) recently reported an 11% year-over-year revenue increase and raised its fiscal 2026 non-GAAP earnings per share (EPS) guidance. These developments have coincided with stronger demand for high-margin specialty drugs, driving renewed investor attention to the stock. The positive momentum is reflected in...
JPMorgan Chase recently raised its price target on Cardinal Health (NYSE:CAH) to $215 per share, reflecting continued analyst interest in the healthcare distributor's fundamentals. The article contextualizes this bullish rating against a backdrop of recent stock volatility, noting that CAH shares actually saw a 7.8%...
